Phase 3 clinical trials have demonstrated the efficacy of alpelisib against hormone receptor (HR)‐positive, human epithelial growth factor 2 (HER2)‐negative breast cancer {André, 2019 #2846}, leading to its approval by the FDA in 2019 {Alves, 2023 #2847}. This evidence concerns the gene NR4A1 and breast carcinoma.